Loading blog posts...
April 23, 2026 • 2 min read
Quest Diagnostics (NYSE: DGX) is a household name in the healthcare sector, providing crucial diagnostic testing and information services to millions of patients and providers across the United States. From routine blood work to complex genetic and oncology testing, their vast network of labs forms the backbone of many medical decisions. Today, we are digging into their latest 10-Q filing to unpack their income statement, see how their core business is performing, and pull out some key insights for the quarter ended March 31, 2026.
The first quarter paints a robust financial picture for Quest Diagnostics. Total net revenues grew by a healthy 9.2% year-over-year to $2.895 billion. This top-line growth carried through the income statement, with operating income jumping a notable 15.5% to $399 million. The result was a net income attributable to the company of $252 million, translating to a diluted earnings per share (EPS) of $2.24, up from $1.94 in Q1 2025.
The flow from revenue to profit for the quarter is illustrated in the diagram below.
So, what's fueling this growth? The story lies in the company's core Diagnostic Information Services (DIS) segment, which accounts for nearly 98% of total revenue. This segment saw its revenue climb 9.4% to $2.83 billion, driven almost entirely by a 10.8% increase in organic requisition volume. This suggests strong underlying demand for their testing services, a positive sign of fundamental business health.
Quest also demonstrated effective cost management. While revenues grew over 9%, total operating costs increased by a slower 8.2%. As a percentage of revenue, both Cost of Services and Selling, General and Administrative (SG&A) expenses decreased slightly compared to the same quarter last year. This operational leverage is what allowed operating income to grow faster than revenue, boosting the company's operating margin to 13.8% from 13.0%.
Quest Diagnostics' first-quarter results for 2026 show a company firing on all cylinders. The impressive organic growth in its core business, coupled with improved profitability, points to a healthy start to the year. Beyond the numbers, strategic moves like their recent venture with Corewell Health indicate a focus on expanding their reach and capabilities. For investors, this filing presents a picture of a mature industry leader that is still finding effective ways to grow both its top and bottom lines.
Last updated: April 23, 2026
